Bayer AG

BAYN

DE000BAY0017

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

96,567

Sector

Pharmaceuticals

Calendar

05/11/2024 - Q3 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX Europe 600 Index (EUR) , DAX

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

BAYER : Crop Science’s weaker 2024

August 19, 2024 at 04:40 pm IST

Bayer AG: Not out of the woods yet

March 06, 2024 at 09:16 pm IST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.91EUR

Average target price

35.59EUR

Spread / Average Target

+23.11%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 02:33:22 09/09/2024 pm IST			5-day change	1st Jan Change
28.94 ^EUR	+0.09%		+2.89%	-14.24%

06/09	Bayer: last-minute presentations at ESMO congress	CF
06/09	Veeva Systems: leader in cloud solutions for the life sciences industry

Bayer: last-minute presentations at ESMO congress	06/09	CF
Veeva Systems: leader in cloud solutions for the life sciences industry	06/09
Bayer's bottoming out continues to take shape - BofA commentary	06/09	DP
Bayer gains significantly - focus on US glyphosate dispute	05/09	DP
Bayer: new data for menopause treatment	05/09	CF
Bayer: will present new data at ESMO	05/09	CF
WDH: Fewer crop protection products planned for fields	04/09	DP
Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause	04/09	CI
Expert dialog recommends restructuring EU agricultural policy	04/09	DP
Transcript : Bayer Aktiengesellschaft Presents at Barclays 17th Annual Global Consumer Staples Conference, Sep-03-2024 04:29 PM	04/09
Bayer: FDA approval for investigational drug	03/09	CF
US will still pay at least twice as much after negotiating drug prices	03/09	RE
Transcript : Bayer Aktiengesellschaft - Special Call	02/09
Bayer: positive study on finerenone in cardiology	02/09	CF
Goldman rates Bayer 'Neutral' - Target 30 euros	02/09	DP
BAYER AG : Goldman Sachs remains Neutral	02/09	ZD
BAYER AG : JP Morgan gives a Neutral rating	02/09	ZD
BAYER AG : UBS reiterates its Neutral rating	02/09	ZD
Bayer in demand - Analyst: Kerendia result sufficient for approval	02/09	DP
Bayer's Finerenone Treatment Shows Promising Results in Heart Failure Patients	02/09	MT
Bayer Announces Late-Breaking KERENDIA® Investigational Data Presented	01/09	CI
German Inflation's Cooling Surprise Boosts Local Shares	29/08	MT
Bayer: new CEO for Bayer HealthCare in France	29/08	CF
Bayer: first patient enrolled in phase III trial	29/08	CF
Bayer to Present Phase III Kerendia Data	29/08	CI

Bayer AG

Equities